2019 Future of Brain Ischemia R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments
The global demand for Brain Ischemia treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Brain Ischemia pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Brain Ischemia pipeline companies from advancing their products into Phase 3 or Phase 4.
Brain Ischemia Report Description-
The 2019 pipeline study on Brain Ischemia pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Brain Ischemia pipeline compounds.
The Brain Ischemia pipeline guide presents information on all active drugs currently being developed for Brain Ischemia. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.
Details of current status, R&D progress and latest developments for every Brain Ischemia pipeline candidate are analyzed.
Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Brain Ischemia drug candidates.
Drug development companies, collaborators, originating companies, license providers and universities participating in the Brain Ischemia product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.
The report assists in identifying potential upcoming companies and drugs in Brain Ischemia pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.
Scope of Brain Ischemia pipeline report includes-
Brain Ischemia Report Description-
The 2019 pipeline study on Brain Ischemia pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Brain Ischemia pipeline compounds.
The Brain Ischemia pipeline guide presents information on all active drugs currently being developed for Brain Ischemia. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.
Details of current status, R&D progress and latest developments for every Brain Ischemia pipeline candidate are analyzed.
Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Brain Ischemia drug candidates.
Drug development companies, collaborators, originating companies, license providers and universities participating in the Brain Ischemia product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.
The report assists in identifying potential upcoming companies and drugs in Brain Ischemia pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.
Scope of Brain Ischemia pipeline report includes-
- An overview of Brain Ischemia disease including symptoms, causes, diagnosis and available treatment options is provided.
- Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
- Phase wise count of Brain Ischemia pipeline
- Company wise list of Brain Ischemia pipeline
- Mechanism of Action wise Brain Ischemia pipeline
- For each pipeline candidate, the following details are provided
- Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
- Current status of development
- Drug overview
- Mechanism of Action
- Pre-clinical and Clinical Trials/Results
- Company Overview and Recent Developments
- The report is designed to help industry executives promote the success and continued growth of their organizations
- Get clear understanding of the entire Brain Ischemia pipeline, with details on active projects
- Stay ahead of the competition through comprehensive knowledge of Brain Ischemia pipeline progress
- Get in detail information of each product with updated information on each project along with key milestones
- Gain clear insights into companies participating in Brain Ischemia pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
- Get trial information for each pipeline product under development
- Understand the pipeline structure in terms of mechanism of Action, phase and company
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. GLOBAL BRAIN ISCHEMIA PIPELINE OVERVIEW
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Research Methodology
3. EXECUTIVE SUMMARY
3.1 Brain Ischemia Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development
3.2.1 Pre-clinical
3.2.2 Discovery
3.2.3 Phase
3.2.4Phase
3.3 Pipeline Drugs in Advanced Stage of Development
3.3.1 Phase
3.3.2 Pre-registration
3.4 Companies involved in Brain Ischemia pipeline, H1- 2019
3.5 Mechanism of Action wise Brain Ischemia Pipeline Candidates
4 ARANDA PHARMA LTD BRAIN ISCHEMIA PIPELINE DETAILS
4.1 Aranda Pharma Ltd Business Profile
4.2 Aranda Pharma Ltd Brain Ischemia Drug Details
4.3 Drug Snapshot
4.3.1 Originator
4.3.2 Collaborator/Co-Developer
4.3.3 Route of Administration
4.3.4 Orphan Drug/Fast Track/Special Designation
4.3.5 Geography
4.3.6 Type of Molecular Entity
4.3.7 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments
5 ARONORA INC BRAIN ISCHEMIA PIPELINE DETAILS
5.1 Aronora Inc Business Profile
5.2 Aronora Inc Brain Ischemia Drug Details
5.3 Drug Snapshot
5.3.1 Originator
5.3.2 Collaborator/Co-Developer
5.3.3 Route of Administration
5.3.4 Orphan Drug/Fast Track/Special Designation
5.3.5 Geography
5.3.6 Type of Molecular Entity
5.3.7 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments
6 COHBAR INC BRAIN ISCHEMIA PIPELINE DETAILS
6.1 CohBar Inc Business Profile
6.2 CohBar Inc Brain Ischemia Drug Details
6.3 Drug Snapshot
6.3.1 Originator
6.3.2 Collaborator/Co-Developer
6.3.3 Route of Administration
6.3.4 Orphan Drug/Fast Track/Special Designation
6.3.5 Geography
6.3.6 Type of Molecular Entity
6.3.7 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments
7 LIXTE BIOTECHNOLOGY HOLDINGS BRAIN ISCHEMIA PIPELINE DETAILS
7.1 Lixte Biotechnology Holdings Business Profile
7.2 Lixte Biotechnology Holdings Brain Ischemia Drug Details
7.3 Drug Snapshot
7.3.1 Originator
7.3.2 Collaborator/Co-Developer
7.3.3 Route of Administration
7.3.4 Orphan Drug/Fast Track/Special Designation
7.3.5 Geography
7.3.6 Type of Molecular Entity
7.3.7 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments
8 NEURONASCENT INC BRAIN ISCHEMIA PIPELINE DETAILS
8.1 NeuroNascent Inc Business Profile
8.2 NeuroNascent Inc Brain Ischemia Drug Details
8.3 Drug Snapshot
8.3.1 Originator
8.3.2 Collaborator/Co-Developer
8.3.3 Route of Administration
8.3.4 Orphan Drug/Fast Track/Special Designation
8.3.5 Geography
8.3.6 Type of Molecular Entity
8.3.7 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments
9 NEUROP INC BRAIN ISCHEMIA PIPELINE DETAILS
9.1 NeurOp Inc Business Profile
9.2 NeurOp Inc Brain Ischemia Drug Details
9.3 Drug Snapshot
9.3.1 Originator
9.3.2 Collaborator/Co-Developer
9.3.3 Route of Administration
9.3.4 Orphan Drug/Fast Track/Special Designation
9.3.5 Geography
9.3.6 Type of Molecular Entity
9.3.7 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments
10 NONO INC BRAIN ISCHEMIA PIPELINE DETAILS
10.1 NoNO Inc Business Profile
10.2 NoNO Inc Brain Ischemia Drug Details
10.3 Drug Snapshot
10.3.1 Originator
10.3.2 Collaborator/Co-Developer
10.3.3 Route of Administration
10.3.4 Orphan Drug/Fast Track/Special Designation
10.3.5 Geography
10.3.6 Type of Molecular Entity
10.3.7 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments
11 PROLONG PHARMACEUTICALS, LLC BRAIN ISCHEMIA PIPELINE DETAILS
11.1 Prolong Pharmaceuticals, LLC Business Profile
11.2 Prolong Pharmaceuticals, LLC Brain Ischemia Drug Details
11.3 Drug Snapshot
11.3.1 Originator
11.3.2 Collaborator/Co-Developer
11.3.3 Route of Administration
11.3.4 Orphan Drug/Fast Track/Special Designation
11.3.5 Geography
11.3.6 Type of Molecular Entity
11.3.7 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments
12 VECT-HORUS SAS BRAIN ISCHEMIA PIPELINE DETAILS
12.1 Vect-Horus SAS Business Profile
12.2 Vect-Horus SAS Brain Ischemia Drug Details
12.3 Drug Snapshot
12.3.1 Originator
12.3.2 Collaborator/Co-Developer
12.3.3 Route of Administration
12.3.4 Orphan Drug/Fast Track/Special Designation
12.3.5 Geography
12.3.6 Type of Molecular Entity
12.3.7 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments
13. LATEST BRAIN ISCHEMIA DRUG PIPELINE DEVELOPMENTS, 2019
14. APPENDIX
14.1 About Us
14.2 Sources and Methodology
14.3 Contact Information
1.1 List of Tables
1.2 List of Figures
2. GLOBAL BRAIN ISCHEMIA PIPELINE OVERVIEW
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Research Methodology
3. EXECUTIVE SUMMARY
3.1 Brain Ischemia Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development
3.2.1 Pre-clinical
3.2.2 Discovery
3.2.3 Phase
3.2.4Phase
3.3 Pipeline Drugs in Advanced Stage of Development
3.3.1 Phase
3.3.2 Pre-registration
3.4 Companies involved in Brain Ischemia pipeline, H1- 2019
3.5 Mechanism of Action wise Brain Ischemia Pipeline Candidates
4 ARANDA PHARMA LTD BRAIN ISCHEMIA PIPELINE DETAILS
4.1 Aranda Pharma Ltd Business Profile
4.2 Aranda Pharma Ltd Brain Ischemia Drug Details
4.3 Drug Snapshot
4.3.1 Originator
4.3.2 Collaborator/Co-Developer
4.3.3 Route of Administration
4.3.4 Orphan Drug/Fast Track/Special Designation
4.3.5 Geography
4.3.6 Type of Molecular Entity
4.3.7 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments
5 ARONORA INC BRAIN ISCHEMIA PIPELINE DETAILS
5.1 Aronora Inc Business Profile
5.2 Aronora Inc Brain Ischemia Drug Details
5.3 Drug Snapshot
5.3.1 Originator
5.3.2 Collaborator/Co-Developer
5.3.3 Route of Administration
5.3.4 Orphan Drug/Fast Track/Special Designation
5.3.5 Geography
5.3.6 Type of Molecular Entity
5.3.7 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments
6 COHBAR INC BRAIN ISCHEMIA PIPELINE DETAILS
6.1 CohBar Inc Business Profile
6.2 CohBar Inc Brain Ischemia Drug Details
6.3 Drug Snapshot
6.3.1 Originator
6.3.2 Collaborator/Co-Developer
6.3.3 Route of Administration
6.3.4 Orphan Drug/Fast Track/Special Designation
6.3.5 Geography
6.3.6 Type of Molecular Entity
6.3.7 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments
7 LIXTE BIOTECHNOLOGY HOLDINGS BRAIN ISCHEMIA PIPELINE DETAILS
7.1 Lixte Biotechnology Holdings Business Profile
7.2 Lixte Biotechnology Holdings Brain Ischemia Drug Details
7.3 Drug Snapshot
7.3.1 Originator
7.3.2 Collaborator/Co-Developer
7.3.3 Route of Administration
7.3.4 Orphan Drug/Fast Track/Special Designation
7.3.5 Geography
7.3.6 Type of Molecular Entity
7.3.7 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments
8 NEURONASCENT INC BRAIN ISCHEMIA PIPELINE DETAILS
8.1 NeuroNascent Inc Business Profile
8.2 NeuroNascent Inc Brain Ischemia Drug Details
8.3 Drug Snapshot
8.3.1 Originator
8.3.2 Collaborator/Co-Developer
8.3.3 Route of Administration
8.3.4 Orphan Drug/Fast Track/Special Designation
8.3.5 Geography
8.3.6 Type of Molecular Entity
8.3.7 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments
9 NEUROP INC BRAIN ISCHEMIA PIPELINE DETAILS
9.1 NeurOp Inc Business Profile
9.2 NeurOp Inc Brain Ischemia Drug Details
9.3 Drug Snapshot
9.3.1 Originator
9.3.2 Collaborator/Co-Developer
9.3.3 Route of Administration
9.3.4 Orphan Drug/Fast Track/Special Designation
9.3.5 Geography
9.3.6 Type of Molecular Entity
9.3.7 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments
10 NONO INC BRAIN ISCHEMIA PIPELINE DETAILS
10.1 NoNO Inc Business Profile
10.2 NoNO Inc Brain Ischemia Drug Details
10.3 Drug Snapshot
10.3.1 Originator
10.3.2 Collaborator/Co-Developer
10.3.3 Route of Administration
10.3.4 Orphan Drug/Fast Track/Special Designation
10.3.5 Geography
10.3.6 Type of Molecular Entity
10.3.7 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments
11 PROLONG PHARMACEUTICALS, LLC BRAIN ISCHEMIA PIPELINE DETAILS
11.1 Prolong Pharmaceuticals, LLC Business Profile
11.2 Prolong Pharmaceuticals, LLC Brain Ischemia Drug Details
11.3 Drug Snapshot
11.3.1 Originator
11.3.2 Collaborator/Co-Developer
11.3.3 Route of Administration
11.3.4 Orphan Drug/Fast Track/Special Designation
11.3.5 Geography
11.3.6 Type of Molecular Entity
11.3.7 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments
12 VECT-HORUS SAS BRAIN ISCHEMIA PIPELINE DETAILS
12.1 Vect-Horus SAS Business Profile
12.2 Vect-Horus SAS Brain Ischemia Drug Details
12.3 Drug Snapshot
12.3.1 Originator
12.3.2 Collaborator/Co-Developer
12.3.3 Route of Administration
12.3.4 Orphan Drug/Fast Track/Special Designation
12.3.5 Geography
12.3.6 Type of Molecular Entity
12.3.7 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments
13. LATEST BRAIN ISCHEMIA DRUG PIPELINE DEVELOPMENTS, 2019
14. APPENDIX
14.1 About Us
14.2 Sources and Methodology
14.3 Contact Information
